The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men
Diabetic Medicine, 04/04/2012
Haugaard SB et al. – In these explorative analyses, the soluble urokinase plasminogen activator receptor associated independently with incident diabetes in non–smokers, supporting an immune origin of Type 2 diabetes. Competing disease risk may explain lack of association among smokers.
The Danish National Diabetes Register enabled more accurate identification of incident diabetes during a median follow-up of 13.8 years in the Danish MONICA 10 cohort (n = 2353 generally healthy individuals).
The soluble urokinase plasminogen activator receptor was measured by the ELISA method.
To fulfil model assumptions, outcome analyses were stratified by age, and further by smoking, owing to the interaction between the soluble urokinase plasminogen activator receptor and smoking on new-onset diabetes (P < 0.0001).
New-onset diabetes (n = 182) was associated with increased soluble urokinase plasminogen activator receptor levels (P = 0.013).
Among 699 middle-aged (41 and 51 years) and 564 older (61 and 71 years) non-smokers, participants in the upper soluble urokinase plasminogen activator receptor quartile had a sex- and age-adjusted relative risk of 6.01 (95% CI 2.17-16.6, P < 0.0006) and relative risk of 3.25 (95% CI 1.51-6.98, P = 0.0025), respectively, for new-onset diabetes compared with participants in the lowest quartile.
This relationship remained significant after additional adjustments for C-reactive protein and leukocytes or fasting glucose and insulin or BMI (P < 0.05).
The soluble urokinase plasminogen activator receptor was not related to incident diabetes among smokers (P ≥ 0.85).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.